Recommended Products
biological source
human
Quality Level
form
lyophilized powder
origin
USA origin
technique(s)
cell culture | mammalian: suitable
impurities
virus, tested
shipped in
dry ice
storage temp.
−20°C
Related Categories
General description
Complement serum is prepared from pooled human plasma and lyophilized from the amount of serum indicated on the label.
Application
Complement sera human has been used:
- to incubate DLD-1 or SW-620 cells to quantify C5a release
- in multiplex bead antibody-binding assay to assay C3d
- in complement-dependent cytotoxicity assay
Complement sera human has been used:
- to incubate DLD-1 or SW-620 cells to quantify C5a release
- in multiplex bead antibody-binding assay to assay C3d
- in complement-dependent cytotoxicity assay
The activity of complement sera can be determined by hemolytic assays in vitro.
Physical form
Lyophilized powder from indicated amount of serum
Analysis Note
Hemolytic titer (CH50 units per ml) is determined by method of Kabat and Mayer. Actual titer given on label.
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
高风险级别生物产品--人源产品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
David A Spencer et al.
Nature communications, 13(1), 662-662 (2022-02-05)
Increasingly, antibodies are being used to treat and prevent viral infections. In the context of HIV, efficacy is primarily attributed to dose-dependent neutralization potency and to a lesser extent Fc-mediated effector functions. It remains unclear whether augmenting effector functions of
Chiaki Kawabata et al.
Biological & pharmaceutical bulletin, 44(2), 219-224 (2021-02-02)
Baculovirus vectors (BVs) are safely able to transduce foreign genes and express them in mammalian cells. However, the transduction activity of BVs is strongly reduced by the attack of serum complement, which is one of the major obstacles in the
S Nowicki et al.
Infection and immunity, 63(12), 4790-4794 (1995-12-01)
Human C1q displayed a dose-dependent protection of gonococcal cells (GC) from the bactericidal effect of newborn rat serum. All rat pups injected with C1q-preincubated GC developed bacteremia, while none of the animals injected with GC only were infected. After clearance
Anaïs Thiriard et al.
Frontiers in immunology, 14, 1107156-1107156 (2023-04-04)
To comprehensively analyze the quality of the antibody response between children with Multisystem inflammatory syndrome (MIS-C) and age-matched controls at one month after SARS-CoV-2 exposure, and infected in the same time-period. Serum from 20 MIS-C children at admission, and 14
Lisa Tomasi et al.
Open forum infectious diseases, 9(11), ofac554-ofac554 (2022-12-06)
The basis of the less severe clinical presentation of coronavirus disease 2019 (COVID-19) in children as compared with adults remains incompletely understood. Studies have suggested that a more potent boosting of immunity to endemic common cold coronaviruses (HCoVs) may protect
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service